GALA-chol TFA

Nanoparticles composed of GALA-chol TFA (10% proportion) and 50 nM siRNA RET/PTC1-SQ reduce the viability of BHP 10-3 SC mice and TPC-1 cells by approximately 20% at 48 h and 72 h (treatment duration: 24-72 h), and the inhibitory effect is enhanced (by approximately 50%) when combined with Lipofectamine 2000^[1].
Nanoparticles composed of GALA-chol TFA and siRNA RET/PTC1-SQ (10% GALA-chol TFA; 50 nM siRNA; 24-48 h) significantly inhibit the expression of RET/PTC1 gene and protein in BHP 10-3 SC mice and TPC-1 cells at both 24 h and 48 h, whereas siRNA RET/PTC1-SQ nanoparticles without GALA-chol TFA exhibit no silencing activity^[1].
Nanoparticles composed of GALA-chol TFA and siRNA RET/PTC1-SQ (10% GALA-chol TFA; 50 nM siRNA; 4 h) are efficiently internalized by BHP 10-3 SCmice cells, while siRNA RET/PTC1-SQ nanoparticles without GALA-chol TFA cannot cross the cell membrane^[1].
After functional modification of sEVs derived from MCF-7 cells with GALA-chol (0-10 μM/10⁹ sEV particles) TFA, the cytoplasmic cargo delivery efficiency to MCF-7 cells reaches the maximum at a concentration of 8 μM/10⁹ particles; at higher concentrations, the delivery efficiency decreases due to steric hindrance interference^[2].
MCF-7-derived sEVs functionalized with GALA-chol (8 μM/10⁹ sEV particles; 0-10 h) TFA enable efficient lysosomal escape of cargo in MCF-7 cells after 6 h of incubation, showing a significant increase in cytoplasmic cargo distribution compared with non-functionalized sEVs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.